Biosimilar Barricade Breached: Amgen Manufacturing Patents Ruled Not Infringed
Executive Summary
Apotex's Neulasta and Neupogen biosimilars do not infringe Amgen's patent, showing sponsors can get around innovator's manufacturing process patents.
You may also be interested in...
Humira Biosimilar: Boehringer Faces Same Launch Hurdles As Amgen
AbbVie seeks injunction against Boehringer Ingelheim's Cyltezo claiming infringement of 74 patents, 8 of which are in the initial round of litigation; as of Aug. 2, BI had not given 180-day launch notice.
Humira Biosimilar: Boehringer Faces Same Launch Hurdles As Amgen
AbbVie seeks injunction against Boehringer Ingelheim's Cyltezo claiming infringement of 74 patents, 8 of which are in the initial round of litigation; as of Aug. 2, BI had not given 180-day launch notice.
Biosimilar Launch Notification May Head Back To Court
Apotex wants Supreme Court to say that firm doesn't have to wait until FDA licensure of its pegfilgrastim and filgrastim biosimilars to provide Amgen 180-day notice of commercial marketing; Solicitor General has yet to weigh in on similar Sandoz petition.